First Berlin Equity Research publishes independent analysis of Cyxone
Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first half-year of 2020 and was published on 8 September 2020, where First Berlin reviewed the company’s potential with an expected but continued positive outcome. The report in English can be read in its entirety on the Cyxone’s website. Contact Tara Heitner, CEOTel: +46 70 781 88 08Email: tara.heitner@cyxone.com Adelgatan 21211 22